Accelerate Diagnostics Inc AXDX

NAS: AXDX | ISIN: US00430H1023   26/04/2024
0,930 USD (-1,61%)
(-1,61%)   26/04/2024

28 maart 2024 · Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results · Persbericht

7 maart 2024 · Accelerate Diagnostics Scheduled Call to Review 2023 Fourth Quarter and Full Year Results. · Persbericht

19 januari 2024 · Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement · Persbericht

16 januari 2024 · Accelerate Diagnostics Announces Launch of Proposed Public Offering · Persbericht

8 januari 2024 · Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results · Persbericht

9 november 2023 · Accelerate Diagnostics Reports Third Quarter 2023 Results · Persbericht

30 oktober 2023 · Accelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results. · Persbericht

10 augustus 2023 · Accelerate Diagnostics Reports Second Quarter 2023 Financial Results · Persbericht

27 juli 2023 · Accelerate Diagnostics Scheduled Call to Review 2023 Second Quarter Results · Persbericht

10 juli 2023 · Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split · Persbericht

13 juni 2023 · Accelerate Diagnostics Announces Successful Completion of Debt Restructuring Support Agreement, Supporting Advancement of Next-Generation Platform Wave · Persbericht

11 mei 2023 · Accelerate Diagnostics Reports First Quarter 2023 Financial Results · Persbericht

27 april 2023 · Accelerate Diagnostics scheduled call to review 2023 first quarter results · Persbericht

29 maart 2023 · Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results · Persbericht

15 maart 2023 · Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results · Persbericht

15 maart 2023 · Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement · Persbericht

8 maart 2023 · Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors · Persbericht

19 december 2022 · Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansion and breakpoint updates for the Accelerate PhenoTest® BC kit · Persbericht

14 november 2022 · Accelerate Diagnostics Reports Third Quarter 2022 Financial Results · Persbericht

24 oktober 2022 · Accelerate Diagnostics scheduled call to review 2022 third quarter results · Persbericht

Mijn selecties